We examined the effect of inhaled fluticasone diproprionate (FDP) on symptoms, lung function (FEV0.5), and exhaled nitric oxide (FeNO) in infants with recurrent wheeze and raised FeNO. Thirty-one infants aged 6–19 months (mean, 12.7 months; 12 girls) completed the study. All infants had a history of recurrent wheeze and a parental history of atopy. All children had raised FeNO, as determined by an offline tidal breathing technique prior to randomization. Lung function and FeNO were assessed before and after 4 weeks of treatment with FDP or placebo. The parents recorded daily symptoms during the treatment period. Sixteen infants received FDP and 15 the placebo for 4 weeks. At completion of the study, infants treated with FDP had a significant reduction in FeNO (35.0 ppb to 16.5 ppb) compared to those that received placebo (35.2 ppb to 30.2 ppb) (P = 0.05). Small increases in FEV0.5 were observed in both groups, but these changes were not different between groups (P = 0.8). Symptom scores were not significantly different in either group following the intervention. We showed that a moderate dose of inhaled FDP reduces levels of FeNO, a potential marker of airway inflammation, even in the absence of significant changes in lung function and symptoms. © 2004 Wiley-Liss, Inc.
|Number of pages||5|
|Publication status||Published - 1 Sep 2004|